Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.55 |
| ▸ | MAP3K8 | P41279 | 14/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964463 | 0.87 | MAP3K8 (0.59) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL1895808 | 0.87 | MAP3K8 (0.62) | EGFRERBB2MAP3K8 | |
| SCHEMBL4960605 | 0.87 | MAP3K8 (0.65) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL4960545 | 0.84 | MAP3K8 (0.59) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL4960791 | 0.84 | MAP3K8 (0.57) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL4962214 | 0.83 | MAP3K8 (0.60) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL4959780 | 0.82 | EGFR (0.64) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL4961376 | 0.82 | MAP3K8 (0.54) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL6642578 | 0.82 | EGFR (0.66) | EGFRERBB2MAP3K8 | |
| SCHEMBL6071454 | 0.81 | MAP3K8 (0.54) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171440-B1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | WYETH CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
| US-6355636-B1 | ENZYME INHIBITORS | AMERICAN CYANAMID COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1171440-A1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | American Cyanamid Company (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000066583-A1 | SUBSTITUTED 3-CYANO-[1.7], [1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | AMERICAN CYANAMID COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | EGFR 14/4885ERBB2 4/4885MAP3K8 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.